Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Loredana Puca(Cornell University), Katie Gavyert(Cornell University), Verena Sailer(Cornell University), Vincenza Conteduca(Cornell University), Étienne Dardenne(Cornell University), Michael Sigouros(Cornell University), Kumiko Isse(AbbVie (United States)), Megan Kearney(Epic Sciences (United States)), Aram Vosoughi(Cornell University), Luisa Fernandez(Epic Sciences (United States)), Heng Pan(Cornell University), Samaneh Motanagh(Cornell University), Judy Hess(Cornell University), Adam Donoghue(Cornell University), Andrea Sboner(Cornell University), Yuzhuo Wang(University of British Columbia), Ryan Dittamore(Epic Sciences (United States)), David S. Rickman(Cornell University), David M. Nanus(Cornell University), Scott T. Tagawa(Cornell University), Olivier Elemento(Cornell University), Juan Miguel Mosquera(Cornell University), Laura R. Saunders(AbbVie (United States)), Himisha Beltran(Harvard University)
Cited by 209Open Access
Abstract
loss, and aggressive clinical features. DLL3 in circulating tumor cells was concordant with matched metastatic biopsy (87%). Treatment of DLL3-expressing prostate cancer xenografts with a single dose of SC16LD6.5 resulted in complete and durable responses, whereas DLL3-negative models were insensitive. We highlight a patient with neuroendocrine prostate cancer with a meaningful clinical and radiologic response to SC16LD6.5 when treated on a phase 1 trial. Overall, our findings indicate that DLL3 is preferentially expressed in CRPC-NE and provide rationale for targeting DLL3 in patients with DLL3-positive metastatic prostate cancer.
Related Papers
No related papers found
Powered by citation graph analysis